Hints and tips:
...Merck had been in talks to acquire Seagen last summer, offering about $200 a share, according to people familiar with the matter....
...“Pfizer is very good at selling but historically not renowned as having the R&D engine of a Merck or Lilly....
...The contracts will give the UK access to 1.75m additional courses of Merck Sharp and Dohme’s antiviral Lagevrio and an extra 2.5m courses of Pfizer’s Paxlovid pill....
...“The problem remains that the quality and scale is limited, especially when it comes to labour rights.”...
...Strong demand and limited inventory continue to keep home prices near record levels....
...Merck Sector: PHARMA / HQ: KENILWORTH, us Merck faces a growth challenge because of the loss of exclusivity on its multibillion-dollar cancer drug Keytruda towards the end of the decade....
...Earnings S&P 500 companies scheduled to report results this week include Eli Lilly, Merck, Pfizer, ConocoPhillips, Apple, General Electric, Spotify, Qualcomm, Verizon, General Motors and ExxonMobil among...
...A spokesperson for Merck Sharp & Dohme – the name under which the US group operates in Europe – said it is cooperating fully with the CMA’s investigation, and said: MSD is confident that the proceedings...
...Sharp reductions in the disease’s burden have been recorded in Niger and Malawi....
...Mergers led the US company to become known as Merck Sharp & Dohme, which prompted a 1950s agreement for it to keep exclusive rights to the Merck name in North America while calling itself MSD everywhere...
...Mergers led the US company to become known as Merck Sharp & Dohme, and this spurred a 1950s agreement for it to keep exclusive rights to the family name in North America while calling itself MSD everywhere...
...To closures by Merck Sharp & Dohme, GlaxoSmithKline, Roche and Pfizer has now been added AstraZeneca’s re-organisation and reduction....
...Merck Sharp and Dohme, better known as MSD, has filed a case with Delhi’s High Court claiming that Glenmark, the Mumbai-listed pharmaceutical company, is violating patents on its diabetes drugs, Januvia...
...Merck Sharp and Dohme sells its patented diabetes drug Januvia in India for about $24 per month, 80 per cent lower than its global price....
...Rival Merck was also higher, rising 1.5 per cent to $35.81 as it reported first- quarter earnings that also beat estimates....
...“Emerging markets are increasingly active in this space as limited domestic growth spurs international expansion,” he says....
...The best medical advice was to reduce food fat intake – an approach with limited effect. Endo took a different tack. The human body makes cholesterol using an enzyme called HMG-CoA reductase....
...Few mull the “mega mergers” of the past that brought limited benefit. There the similarities end. Some, such as Novartis of Switzerland, have chosen widespread diversification to support sales....
...Last year, it bought Merck Sharp & Dohme’s Ponders End API manufacturing site in north London. It has not divulged details of either that deal or the Queenborough purchase....
...Merck’s latest 15 per cent price cut for Stocrin in Thailand last month appeared not unrelated to the country’s threat to overturn its patents, for example....
...Meanwhile, sharp gains in the pharmaceutical sector failed to keep the other two indices afloat....
...Merck, meanwhile, jumped 6.8 per cent to €67.73 after the German drugs and chemicals group raised its profitability targets....
...Merck's stock saw limited action while Pfizer's was fractionally lower....
International Edition